Triple negative breast cancer (TNBC) is a complex disease that is no longer simply characterized by the absence of estrogen receptor, progesterone receptor and HER2, but is now recognized as a remodeled signalling system with druggable nodes. This review revisits TNBC biology from three angles: the molecular and network-level basis of the heterogeneous nature of TNBC, a rapidly expanding armamentarium of drugs for TNBC that is now far beyond cytotoxic chemotherapy, and the technical and equity issues that determine whether these advances reach patients. In addition, we examine the insights gained by transcriptomic subtyping, hub-gene network analysis and tumour microenvironment profiling into one another that have collectively uncovered vulnerabilities targeted by PARP inhibitors, immune checkpoint inhibition and, more recently, antibody-drug conjugates targeting Trop-2 or low HER2 expression. The study further explore the ways in which single-cell and spatial transcriptomics are refining the resolution of mapping these vulnerabilities, how artificial intelligence is being employed into multi-omic pipelines to prioritize candidate targets, and how existing racial and geographic disparities in TNBC incidence and outcomes complicate the translation of these discoveries into equitable clinical benefit. Overall, the evidence suggests a transition from a subtype-centric paradigm to a network and access oriented approach for TNBC research and care.